Zokinvy Patent Expiration

Zokinvy is a drug owned by Eiger Biopharmaceuticals Inc. It is protected by 2 US drug patents filed in 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 20, 2027. Details of Zokinvy's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7838531 Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Jul, 2024

(7 days from now)

Active
US8828356 Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Oct, 2024

(2 months from now)

Active


FDA has granted several exclusivities to Zokinvy. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Zokinvy, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Zokinvy.

Exclusivity Information

Zokinvy holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Zokinvy's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2025
Orphan Drug Exclusivity(ODE-324) Nov 20, 2027

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Zokinvy is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zokinvy's family patents as well as insights into ongoing legal events on those patents.

Zokinvy's family patents

Zokinvy has patent protection in a total of 6 countries. It has a significant patent presence in the US with 72.7% of its patents being US patents. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Zokinvy.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Zokinvy's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 20, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Zokinvy Generics:

There are no approved generic versions for Zokinvy as of now.





About Zokinvy

Zokinvy is a drug owned by Eiger Biopharmaceuticals Inc. It is used for reducing the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS). Zokinvy uses Lonafarnib as an active ingredient. Zokinvy was launched by Eiger Biopharms in 2020.

Market Authorisation Date:

Zokinvy was approved by FDA for market use on 20 November, 2020.

NCE-1 date:

NCE-1 date is also known as the four year date as it is four years after the original drug approval. Since the approval date for Zokinvy is 20 November, 2020, its NCE-1 date is estimated to be 20 November, 2024

Active Ingredient:

Zokinvy uses Lonafarnib as the active ingredient. Check out other Drugs and Companies using Lonafarnib ingredient

Treatment:

Zokinvy is used for reducing the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS).

Dosage:

Zokinvy is available in capsule form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
50MG CAPSULE Prescription ORAL
75MG CAPSULE Prescription ORAL